Clinical Trial

Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention

Study acronym: COL BE PCI
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main aim of this trial is to determine whether there are fewer cardiovascular events when patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of optimal standard treatment after treatment with PCI, compared with placebo in combination with optimal standard treatment. More specifically, we aim to investigate the benefits of a daily low dose of colchicine in patients with coronary artery disease after treatment with PCI, to confirm that a daily low dose of colchicine helps prevent additional incidents in coronary artery disease, and to identify a subgroup of patients with CAD who are at increased risk for cardiovascular events and could benefit most from colchicine.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-17; most recent amendment 2024-03-07.
Status change: Not Yet Recruiting → Recruiting 2024-02-20
Trial Details
NCT Number NCT06095765
Lead Sponsor AZ Sint-Jan AV
Collaborators: University Hospital, Ghent, Belgium Health Care Knowledge Centre
Conditions Coronary Artery Disease
Enrollment 2,770 participants
Start Date 2024-01-29
Primary Completion 2027-11-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-08